POS0969 PREDICTIVE FACTORS OF FAVOURABLE EVOLUTION IN GLUCOCORTICOIDS-DEPENDENT POLYMYALGIA RHEUMATICA

Background The main treatment of polymyalgia rheumatica (PMR) are glucocorticoids (GC) with a 6-month decrease target, but 45% patients have an unfavourable evolution relapses or dependence. Poor prognostic factors in PMR understudied and controversial. Objectives aim this work was to identify predictive favourable GC-dependent optimize its management. Methods This used data from the phase III study SEMAPHORE, which compared tocilizumab placebo combination standardized oral GC PMR. Response assessed at week 24 after 6 administrations 8 mg/kg placebo. outcome criterion PMR-AS < 10 dose ≤ 5 mg/day prednisone equivalent reduction ≥ between inclusion 24. prediction based on parameters evaluated univariate then multivariate analysis for variables p <0.2 whole population both arms (tocilizumab placebo). Results At 24, 49% 100 included had fulfilled criterion. In population, being treated predictor (OR: 6.28 (2.49-17.27), p=0.0002). group, absence anemia, renal impairment low HAQ-DI were 13.2 (1.62-166.5613.2), 8.78 (1.19-91.23) 10.16 (2.03-78.66) respectively). No variable related group. Conclusion active disease despite GC, predict by treatment. tocilizumab, comorbidities such as anemia better functional activity associated outcome. identified trated only. REFERENCES: NIL. Acknowledgements: Disclosure Interests None Declared.